Thousand Oaks, CA, United States of America

Jackie Zeqi Sheng

This inventor holds 27 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Gensun Biopharma Inc., Amgen Inc., Other. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jackie Zeqi Sheng. Retrieved from https://idiyas.com/inventor/jackie-zeqi-sheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 70(Granted Patents)

Location History:

Thousand Oaks, CA (US) (2014 - 2024)
Newbury Park, CA (US) (2024)

Company Filing History:

16 out of 16

Gensun Biopharma Inc.

1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Bispecific Antagonist

Checkpoint Regulator

Trispecific T Cell Engagers

Antitumor Antagonists

TGF-β Pathway

AAV Vector Production

GDF-15 Polypeptides

Cancer Treatment

Immune Checkpoint

Ferroportin Antibodies

Metabolic Disorders

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404336 - Bispecific antagonist comprising a LAG-3 binding domain (2025-09-02),

2. 12350333 - Checkpoint regulator antagonists (2025-07-08),

3. 12060434 - Trispecific T cell engagers (2024-08-13),

4. 12018073 - Antagonists targeting the TGF-β pathway (2024-06-25),

5. 11976133 - Bispecific T cell engagers (2024-05-07),

6. 11945873 - Antitumor antagonists (2024-04-02),

7. 11851493 - Trispecific antagonists (2023-12-26),

8. 11834683 - High titer recombinant AAV vector production in adherent and suspension cells (2023-12-05),

9. 11739131 - Growth differentiation factor 15 (GDF-15) polypeptides (2023-08-29),

10. 11667716 - Bispecific antagonist comprising a LAG-3 binding domain (2023-06-06),

11. 11518813 - Trispecific antagonists (2022-12-06),

12. 11517623 - Anti-PD-1 antibodies, antigen-binding portions thereof and checkpoint regulator antogonists comprising the same (2022-12-06),

13. 11078464 - High titer recombinant AAV vector production in adherent and suspension cells (2021-08-03),

14. 11001635 - Antitumor antagonists (2021-05-11),

15. 10894823 - Trispecific inhibitors for cancer treatment (2021-01-19),

Title: Innovator Spotlight: Jackie Zeqi Sheng

Introduction:

Jackie Zeqi Sheng, a prolific inventor based in Thousand Oaks, CA, has made significant contributions in the field of biopharmaceuticals with a total of 20 patents to his name. His innovative work in developing trispecific antagonists and GDF-15 polypeptides showcases his dedication to advancing treatments for various medical conditions.

Latest Patents:

Among his recent patents, Jackie Zeqi Sheng has introduced groundbreaking inventions such as trispecific antagonists - novel antitumor agents that target immune checkpoint regulators, angiogenesis pathways, and TGF pathways. These antagonists offer a promising approach to treating proliferative disorders. Additionally, his work on GDF-15 polypeptides and mutants demonstrates potential applications in addressing metabolic disorders like type 2 diabetes, obesity, and dyslipidemia.

Career Highlights:

During his career, Jackie Zeqi Sheng has made significant contributions to companies like Gensun Biopharma Inc. and Amgen Inc. His expertise and dedication have led to the development of innovative pharmaceutical solutions that have the potential to improve patient outcomes and quality of life.

Collaborations:

Throughout his career, Jackie Zeqi Sheng has collaborated closely with esteemed colleagues such as Bo Liu and YuMei Xiong. These collaborations have played a crucial role in advancing research and development efforts, leading to the successful patenting of novel biopharmaceutical technologies.

Conclusion:

In conclusion, Jackie Zeqi Sheng stands out as a pioneering inventor in the field of biopharmaceuticals, with a remarkable track record of 20 patents to his name. His innovative work in developing trispecific antagonists and GDF-15 polypeptides underscores his commitment to driving advancements in the treatment of proliferative and metabolic disorders. Collaborating with industry leaders, Jackie Zeqi Sheng continues to make significant contributions that have the potential to transform healthcare and benefit patients worldwide.

Profile summary based on public USPTO records.